Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Shares of Eli Lilly jumped 12% in premarket trading Thursday after the pharmaceutical company released Phase 3 trial results ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.

Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest dose and ...

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...

Eli Lilly's Mounjaro enters Indian market, triggering a sharp rise in consultations as obesity rates climb and patients seek ...

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...

A daily pill developed by Eli Lilly significantly lowered blood sugar levels and led to weight loss in people with Type 2 ...